Evidence map›Paper›PMID 35554908›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Detection of SARS-CoV-2 by Mass Spectrometry.

Petra Wandernoth, Katharina Kriegsmann, Jörg Kriegsmann, Mark Kriegsmann

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Petra WandernothMolecular Pathology Trier, Trier, Germany.
Katharina KriegsmannDepartment of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Jörg KriegsmannMolecular Pathology Trier, Trier, Germany.
Mark KriegsmannInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. mark.kriegsmann@med.uni-heidelberg.de.
University Hospital Heidelberg · DETrier University of Applied Sciences · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amplification of viral ribonucleic acid by real-time reverse transcriptase polymerase chain reaction is the gold standard to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, alternative reliable, fast, and cost-effective methods for the detection of SARS-CoV-2 are still needed. In this chapter, the mass spectrometry-based detection of amplified polymerase chain reaction products of SARS-CoV-2 genes from oral or nasopharyngeal swabs is described. The respective SARS-CoV-2 test has previously been shown to meet standard quality criteria and was therefore approved by the authorities in Europe and the USA.

Indexed as

COVID-19SARS-CoV-2HumansMass SpectrometryNasopharynxReal-Time Polymerase Chain ReactionRNA, ViralRNA, ViralCOVID-19MassARRAYMass SpectrometrySARS-CoV-2

Identifiers

PMID35554908
OpenAlexW4285210825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.